This site is intended for US eye care professionals only.

SYFOVRE has a demonstrated safety profile in OAKS and DERBY with over 1200 patients1

OAKS and DERBY Icon

ADVERSE REACTIONS IN STUDY EYE REPORTED IN ≥2% OF PATIENTS TREATED
WITH SYFOVRE THROUGH YEAR 2 IN A COMBINED ANALYSIS

 

SYFOVRE
MONTHLY
(n=419)

SYFOVRE
EOM
(n=420)

SHAM
POOLED
(n=417)

Ocular discomfort*

13%

10%

11%

Neovascular age-related macular degeneration* >

12%

7%

3%

Vitreous floaters

10%

7%

1%

Conjunctival hemorrhage

8%

8%

4%

Vitreous detachment

4%

6%

3%

Retinal hemorrhage

4%

5%

3%

Punctate keratitis*

5%

3%

<1%

Posterior capsule opacification

4%

4%

3%

Intraocular inflammation* >

4%

2%

<1%

Intraocular pressure increased

2%

3%

<1%

Additional Selected Safety Events

Optic Ischemic Neuropathy

1.7%

0.2%

0.0%

Deaths

6.7%

3.6%

3.8%

  • No events of occlusive or nonocclusive retinitis or vasculitis in clinical trial2
    • Events of retinal vasculitis and /or retinal vascular occlusion have been reported in the real-world setting at an estimated rate of 1/10,000 (0.01%) per injection2†
    • Retinal vasculitis appears to be a first injection phenomenon at an estimated rate of 1/4000 (0.025%) per first injection, and may result in severe vision loss2†
    • Discontinue treatment with SYFOVRE in patients who develop these events1

*The following reported items were combined1:

  • Ocular discomfort included: eye pain, eye irritation, foreign body sensation in eyes, ocular discomfort, abnormal sensation in eye
  • Neovascular age-related macular degeneration included: exudative age-related macular degeneration, choroidal neovascularization
  • Punctate keratitis included: punctate keratitis, keratitis
  • Intraocular inflammation included: vitritis, vitreal cells, iridocyclitis, uveitis, anterior chamber cells, iritis, anterior chamber flare

†Data on file from clinical trial and estimated real-world injections as of March 31, 2024. Injections are calculated based on vials distributed to eyecare professional practices and estimates of patient numbers (extrapolated from licensed data and inventory levels from key accounts, representative of our market).

Scroll to see full chart →Scroll to see more

OAKS and DERBY Icon

IN GALE YEAR 1: ADVERSE REACTIONS IN STUDY EYE REPORTED IN >2% OF
PATIENTS TREATED WITH SYFOVRE*

 

CONTINUED TREATMENT

SYFOVRE
MONTHLY
(n=250)

SYFOVRE
EOM
(n=268)

PREVIOUSLY UNTREATED

SYFOVRE
MONTHLY
(n=129)

SYFOVRE
EOM
(n=143)

Ocular discomfort*

4%

3%

6%

7%

nAMD*

8%

2%

6%

3%

Cataract

5%

2%

4%

4%

Vitreous floaters

4%

2%

10%

6%

Conjunctival hemorrhage

3%

3%

9%

4%

Retinal hemorrhage

3%

2%

2%

1%

Intraocular pressure increased

5%

5%

4%

1%

AEs of interest in study eye, patient (%) events

Infectious endophthalmitis

0

0

1(0.8%)

0

Intraocular inflammation

6(2.4%)

2(0.7%)

5(3.9%)

2(1.4%)

Ischemic optic neuropathy

1(0.4%)

0

0

0

Learn about AEs of interest in GALE >

  • Years 0-3 rates (OAKS, DERBY, and GALE)2:
    • Infectious endophthalmitis: ~1/3600 injections (0.03% per injection)
    • ION: ~1/2000 injections (0.05% per injection)
    • IOI: ~1/360 injections (0.28% per injection)
  • No study events of occlusive or nonocclusive retinitis or vasculitis were reported in clinical trials2
    • Events of retinal vasculitis and/or retinal vascular occlusion have been reported in the real-world setting at an estimated rate of 1/10,000 (0.01%) per injection2†
    • Retinal vasculitis appears to be a first injection phenomenon at an estimated rate of ~1/4000 (0.025%) per first injection and may result in severe vision loss2†
    • Discontinue treatment with SYFOVRE in patients who develop these events1

*The following reported items were combined:

  • Ocular discomfort included: eye pain, eye irritation, foreign body sensation in eyes, ocular discomfort, abnormal sensation in eye
  • Neovascular age-related macular degeneration included: exudative age-related macular degeneration, choroidal neovascularization

†Data on file from clinical trial and estimated real-world injections as of March 31, 2024. Injections are calculated based on vials distributed to eyecare professional practices and estimates of patient numbers (extrapolated from licensed data and inventory levels from key accounts, representative of our market).

AE=adverse event; EOM=every other month; GA=geographic atrophy; ION=optic ischemic neuropathy; nAMD=neovascular age-related macular degeneration.

Back
GALE Efficacy
Next
ApellisAssist

References:  1. SYFOVRE (pegcetacoplan injection) [package insert]. Waltham, MA: Apellis Pharmaceuticals, Inc.; 2023. 2. Data on file. Apellis Pharmaceuticals, Inc.

Show more Show less

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

  • SYFOVRE is contraindicated in patients with ocular or periocular infections, and in patients with active intraocular inflammation

WARNINGS AND PRECAUTIONS

  • Endophthalmitis and Retinal Detachments
    • Intravitreal injections, including those with SYFOVRE, may be associated with endophthalmitis and retinal detachments. Proper aseptic injection technique must always be used when administering SYFOVRE to minimize the risk of endophthalmitis. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay and should be managed appropriately.
  • Retinal Vasculitis and/or Retinal Vascular Occlusion
    • Retinal vasculitis and/or retinal vascular occlusion, typically in the presence of intraocular inflammation, have been reported with the use of SYFOVRE. Cases may occur with the first dose of SYFOVRE and may result in severe vision loss. Discontinue treatment with SYFOVRE in patients who develop these events. Patients should be instructed to report any change in vision without delay.
  • Neovascular AMD
    • In clinical trials, use of SYFOVRE was associated with increased rates of neovascular (wet) AMD or choroidal neovascularization (12% when administered monthly, 7% when administered every other month and 3% in the control group) by Month 24. Patients receiving SYFOVRE should be monitored for signs of neovascular AMD. In case anti-Vascular Endothelial Growth Factor (anti-VEGF) is required, it should be given separately from SYFOVRE administration.
  • Intraocular Inflammation
    • In clinical trials, use of SYFOVRE was associated with episodes of intraocular inflammation including: vitritis, vitreal cells, iridocyclitis, uveitis, anterior chamber cells, iritis, and anterior chamber flare. After inflammation resolves, patients may resume treatment with SYFOVRE.
  • Increased Intraocular Pressure
    • Acute increase in IOP may occur within minutes of any intravitreal injection, including with SYFOVRE. Perfusion of the optic nerve head should be monitored following the injection and managed as needed.

ADVERSE REACTIONS

  • Most common adverse reactions (incidence ≥5%) are ocular discomfort, neovascular age-related macular degeneration, vitreous floaters, conjunctival hemorrhage.

INDICATION

SYFOVRE® (pegcetacoplan injection) is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Please see full Prescribing Information for more information.

INDICATION

SYFOVRE® (pegcetacoplan injection) is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

  • SYFOVRE is contraindicated in patients with ocular or periocular infections, and in patients with active intraocular inflammation

WARNINGS AND PRECAUTIONS

  • Endophthalmitis and Retinal Detachments
    • Intravitreal injections, including those with SYFOVRE, may be associated with endophthalmitis and retinal detachments. Proper aseptic injection technique must always be used when administering SYFOVRE to minimize the risk of endophthalmitis. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay and should be managed appropriately.
  • Retinal Vasculitis and/or Retinal Vascular Occlusion
    • Retinal vasculitis and/or retinal vascular occlusion, typically in the presence of intraocular inflammation, have been reported with the use of SYFOVRE. Cases may occur with the first dose of SYFOVRE and may result in severe vision loss. Discontinue treatment with SYFOVRE in patients who develop these events. Patients should be instructed to report any change in vision without delay.
  • Neovascular AMD
    • In clinical trials, use of SYFOVRE was associated with increased rates of neovascular (wet) AMD or choroidal neovascularization (12% when administered monthly, 7% when administered every other month and 3% in the control group) by Month 24. Patients receiving SYFOVRE should be monitored for signs of neovascular AMD. In case anti-Vascular Endothelial Growth Factor (anti-VEGF) is required, it should be given separately from SYFOVRE administration.
  • Intraocular Inflammation
    • In clinical trials, use of SYFOVRE was associated with episodes of intraocular inflammation including: vitritis, vitreal cells, iridocyclitis, uveitis, anterior chamber cells, iritis, and anterior chamber flare. After inflammation resolves, patients may resume treatment with SYFOVRE.
  • Increased Intraocular Pressure
    • Acute increase in IOP may occur within minutes of any intravitreal injection, including with SYFOVRE. Perfusion of the optic nerve head should be monitored following the injection and managed as needed.

ADVERSE REACTIONS

  • Most common adverse reactions (incidence ≥5%) are ocular discomfort, neovascular age-related macular degeneration, vitreous floaters, conjunctival hemorrhage.

INDICATION

SYFOVRE® (pegcetacoplan injection) is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Please see full Prescribing Information for more information.

INDICATION

SYFOVRE® (pegcetacoplan injection) is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).